X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
Aversa (fentanyl) abuse-deterrent transdermal technology can be utilized to incorporate aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential.
Lead Product(s): Fentanyl
Therapeutic Area: Neurology Product Name: Aversa Fentanyl
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 27, 2024
Details:
Kindeva will perform commercial manufacturing process development and manufacture clinical supplies for Aversa Fentanyl, which combines Nutriband's AVERSA™ abuse-deterrent transdermal technology with Kindeva's FDA-approved transdermal fentanyl patch system.
Lead Product(s): Fentanyl
Therapeutic Area: Neurology Product Name: Aversa Fentanyl
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Nutriband
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 05, 2024
Details:
The joint venture collaboration comprises 13 brands across 6 therapeutic areas primarily focused on pain management, including Abstral (fentanyl) and PecFent for breakthrough cancer pain, Moventig for opioid-induced constipation, and Adcal-D3® for osteoporosis.
Lead Product(s): Fentanyl
Therapeutic Area: Neurology Product Name: Abstral
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Grunenthal
Deal Size: $83.2 million Upfront Cash: Undisclosed
Deal Type: Collaboration August 02, 2023
Details:
The net proceeds will be used to fund the development and regulatory submission process for the Company's patented lead product platform, AVERSA™ Fentanyl, an abuse-deterrent fentanyl transdermal system.
Lead Product(s): Fentanyl
Therapeutic Area: Neurology Product Name: Aversa
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing July 14, 2023
Details:
AVERSA™ (fentanyl) combines Nutriband’s proprietary AVERSA™ abuse-deterrent transdermal technology and Kindeva’s FDA-approved transdermal fentanyl patch system.
Lead Product(s): Fentanyl
Therapeutic Area: Neurology Product Name: Aversa
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Kindeva Drug Delivery
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 04, 2023
Details:
The financing will be used for commercialising AVERSA™ Fentanyl, an abuse-deterrent fentanyl transdermal system. AVERSA™ Fentanyl contains Nutriband's proprietary transdermal abuse deterrent technology.
Lead Product(s): Fentanyl
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing March 28, 2023
Details:
Aversa (fentanyl) abuse deterrent technology can be utilized to incorporate aversive agents into transdermal patches to prevent the abuse, diversion, misuse and accidental exposure of drugs with abuse potential such as opioids used to treat moderate to severe chronic pain.
Lead Product(s): Fentanyl
Therapeutic Area: Neurology Product Name: Aversa
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 01, 2022
Details:
Key products in the portfolio include Abstral® and PecFent® (Fentanyl) for breakthrough cancer pain, Moventig® (Naloxegol) for opioid-induced constipation and Adcal-D3® (calcium and vitamin D3) for osteoporosis.
Lead Product(s): Fentanyl
Therapeutic Area: Neurology Product Name: Abstral
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Grunenthal
Deal Size: Undisclosed Upfront Cash: $82.7 million
Deal Type: Collaboration November 24, 2022
Details:
Adalvo will be the sole and exclusive owner of the Onsolis® (fentanyl) and will obtain full rights on the product, taking over all existing business and all market authorizations, globally, including the US.
Lead Product(s): Fentanyl
Therapeutic Area: Neurology Product Name: Onsolis
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Adalvo
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition August 02, 2022
Details:
Aversa (fentanyl) is an abuse deterrent transdermal technology that incorporates aversive agents to prevent the abuse, diversion, misuse and accidental exposure of drugs with abuse potential, specifically opioids.
Lead Product(s): Fentanyl
Therapeutic Area: Neurology Product Name: Aversa
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 01, 2022
Details:
Company’s recent successful uplisting to NASDAQ and financing, has started the commercial development of AVERSA™ Fentanyl, which has the potential to be the world’s first fentanyl transdermal system with abuse deterrent properties.
Lead Product(s): Fentanyl
Therapeutic Area: Neurology Product Name: Aversa
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2021
Details:
The collaboration is intended to accelerate the manufacture and batch release of fentanyl injection; one of the critical medicines needed for the treatment of COVID-19 patients.
Lead Product(s): Fentanyl
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ethypharm
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership June 04, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
